In the latest part of its plan to cut barriers to cell and gene therapy (CGT) development, the FDA has published draft guidance to help developers draw on "existing science" to reduce the need for ...

The US Food and Drug Administration (FDA) has proposed guidance on the types of scientifically valid prior knowledge sponsors should consider when developing certain gene therapies (GT). The agency ...